BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27

• Press Releases

  Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

  February 13, 2026

   · 

  11 min read
• Press Releases

  Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

  February 13, 2026

   · 

  7 min read
• Press Releases

  MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial

  February 13, 2026

   · 

  1 min read
• Press Releases

  Moleculin Launches CEO Corner Platform to Share Strategic Insights

  February 13, 2026

   · 

  4 min read
• Press Releases

  HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

  February 13, 2026

   · 

  10 min read
• Press Releases

  Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray

  February 13, 2026

   · 

  5 min read
• Press Releases

  Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation

  February 13, 2026

   · 

  3 min read
• Press Releases

  Precision Biologics’ New PB-223 ADC Targeting Multiple Cancer Types to Be Highlighted in Keynote at 6th ACE Drug Discovery Summit

  February 13, 2026

   · 

  1 min read
• 

  Earnings

  Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation

  Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.

  February 13, 2026

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Gene therapy

  Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp

  Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.

  February 13, 2026

   · 

  3 min read

   · 

  Dan Samorodnitsky